CBIO vs MRK vs BMY vs CRL vs IQV

For growth investors, IQVIA Holdings Inc.

(IQV) is the stronger pick with 5. 9% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). Bristol-Myers Squibb Company (BMY) offers the better valuation at 16. 5x trailing P/E (9. 0x forward), making it the more compelling value choice. Analysts rate Crescent Biopharma, Inc. (CBIO) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bristol-Myers Squibb Company (BMY) is the cheapest at 16.

5x versus IQVIA Holdings Inc. at 23. 1x. On forward P/E, Bristol-Myers Squibb Company is actually cheaper at 9. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 35x versus Merck & Co. , Inc. 's 1. 09x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Merck & Co.

, Inc. (MRK) delivered a total return of +78. 0%, compared to -93. 3% for Crescent Biopharma, Inc. (CBIO). Over 10 years, the gap is even starker: IQV returned +177. 5% versus CBIO's -97. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Merck & Co.

, Inc. (MRK) is the lower-risk stock at 0. 32β versus Charles River Laboratories International, Inc. 's 1. 39β — meaning CRL is approximately 332% more volatile than MRK relative to the S&P 500. On balance sheet safety, Crescent Biopharma, Inc. (CBIO) carries a lower debt/equity ratio of 1% versus 3% for Bristol-Myers Squibb Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), IQVIA Holdings Inc.

(IQV) is pulling ahead at 5. 9% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Bristol-Myers Squibb Company grew EPS 178. 2% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, CBIO leads at 424. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus -1419. 6% for Crescent Biopharma, Inc. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus -1407. 5% for CBIO. At the gross margin level — before operating expenses — CBIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 35x versus Merck & Co. , Inc. 's 1. 09x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bristol-Myers Squibb Company (BMY) trades at 9. 0x forward P/E versus 23. 2x for Merck & Co. , Inc. — 14. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CBIO: 79. 9% to $33. 00.

In this comparison, BMY (4.

3% yield), MRK (2. 7% yield) pay a dividend. CBIO, CRL, IQV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Merck & Co.

, Inc. (MRK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 32), 2. 7% yield, +169. 6% 10Y return). Both have compounded well over 10 years (MRK: +169. 6%, CRL: +122. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CBIO is a small-cap quality compounder stock; MRK is a large-cap deep-value stock; BMY is a mid-cap deep-value stock; CRL is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock. MRK, BMY pay a dividend while CBIO, CRL, IQV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.